Neurocrine Biosciences to Present at Upcoming Healthcare Confere

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE Neurocrine Biosciences, Inc.

SAN DIEGO, March 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, CEO of Neurocrine Biosciences, will present at the following investor conferences:

  • Cowen and Company 38th Annual Health Care Conference at 10:00 a.m. ET on Wednesday, March 14, 2018, in Boston.
  • Barclays Global Healthcare Conference at 1:35 p.m. ET on Thursday, March 15, 2018, in Miami.
  • Oppenheimer 28th Annual Healthcare Conference at 10:55 a.m. ET on Wednesday, March 21, 2018, in New York City.

The live presentations will be webcast and may be accessed on the Company's website under Investors at A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. The Company markets INGREZZA® (valbenazine) capsules in the United States for the treatment of adults with tardive dyskinesia. INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first FDA approved product indicated for the treatment of adults with tardive dyskinesia. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at


Cision View original content:

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly